A prognostic scoring system that is cheap, efficient and reliable can predict how patients with relapsed and/or metastatic head and neck cancer will respond to immunotherapy, new research has shown.

Urgent investment is needed in advanced forms of radiotherapy so the high-tech treatment can play a central role in clearing the backlog in NHS cancer care that has built up during the pandemic.

Profiling the ‘immune landscape’ of patient’s tumours reveals who will most benefit from radiotherapy with potential immunotherapy in bowel cancer. Tumours which are chronically Inflamed before treatment could be made more susceptible using targeted immunotherapies